Literature DB >> 19371039

Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.

Yijun Deng1, Xilin Zhou, Sita Kugel Desmoulin, Jianmei Wu, Christina Cherian, Zhanjun Hou, Larry H Matherly, Aleem Gangjee.   

Abstract

A series of seven 2-amino-4-oxo-6-substituted thieno[2,3-d]pyrimidines with bridge length variations (from 2 to 8 carbon atoms) were synthesized as selective folate receptor (FR) alpha and beta substrates and as antitumor agents. The syntheses were accomplished from appropriate allylalcohols and 4-iodobenzoate to afford the aldehydes, which were converted to the appropriate 2-amino-4-carbethoxy-5-substituted thiophenes 23-29. Cyclization with chloroformamidine afforded the thieno[2,3-d]pyrimidines 30-36, which were hydrolyzed and coupled with diethyl-L-glutamate, followed by saponification, to give the target compounds 2-8. Compounds 3-6 were potent growth inhibitors (IC(50) 4.7-334 nM) of human tumor cells (KB and IGROV1) that express FRs. In addition, compounds 3-6 inhibited the growth of Chinese hamster ovary (CHO) cells that expressed FRs but not the reduced folate carrier (RFC) or proton-coupled folate transporter (PCFT). However, the compounds were inactive toward CHO cells that lacked FRs but contained either the RFC or PCFT. By nucleoside and 5-amino-4-imidazole carboxamide (AICA) protection studies, along with in vitro and in situ enzyme activity assays, the mechanism of antitumor activity was identified as the dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, AICA ribonucleotide formyltransferase. The dual inhibitory activity of the active thieno[2,3-d]pyrimidine antifolates and the FR specificity represent unique mechanistic features for these compounds distinct from all other known antifolates. The potent inhibitory effects of compounds 3-6 toward cells expressing FRs but not PCFT provide direct evidence that cellular uptake of this series of compounds by FRs does not depend on the presence of PCFT and argues that direct coupling between these transporters is not obligatory.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371039      PMCID: PMC2730022          DOI: 10.1021/jm8011323

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  35 in total

1.  A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.

Authors:  G P Beardsley; B A Moroson; E C Taylor; R G Moran
Journal:  J Biol Chem       Date:  1989-01-05       Impact factor: 5.157

2.  Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin.

Authors:  E C Taylor; P J Harrington; S R Fletcher; G P Beardsley; R G Moran
Journal:  J Med Chem       Date:  1985-07       Impact factor: 7.446

3.  A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.

Authors:  T R Jones; A H Calvert; A L Jackman; S J Brown; M Jones; K R Harrap
Journal:  Eur J Cancer       Date:  1981-01       Impact factor: 9.162

4.  Isolation and partial characterization of three methotrexate-resistant phenotypes from Chinese hamster ovary cells.

Authors:  W F Flintoff; S V Davidson; L Siminovitch
Journal:  Somatic Cell Genet       Date:  1976-05

5.  Quinazoline antifolates inhibiting thymidylate synthase: variation of the N10 substituent.

Authors:  T R Jones; A H Calvert; A L Jackman; M A Eakin; M J Smithers; R F Betteridge; D R Newell; A J Hayter; A Stocker; S J Harland
Journal:  J Med Chem       Date:  1985-10       Impact factor: 7.446

6.  Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells.

Authors:  S C Wong; S A Proefke; A Bhushan; L H Matherly
Journal:  J Biol Chem       Date:  1995-07-21       Impact factor: 5.157

7.  Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.

Authors:  M S Ray; F M Muggia; C G Leichman; S M Grunberg; R L Nelson; R W Dyke; R G Moran
Journal:  J Natl Cancer Inst       Date:  1993-07-21       Impact factor: 13.506

Review 8.  ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer.

Authors:  A L Jackman; D C Farrugia; W Gibson; R Kimbell; K R Harrap; T C Stephens; M Azab; F T Boyle
Journal:  Eur J Cancer       Date:  1995 Jul-Aug       Impact factor: 9.162

9.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.

Authors:  A L Jackman; G A Taylor; W Gibson; R Kimbell; M Brown; A H Calvert; I R Judson; L R Hughes
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

10.  Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.

Authors:  S G Smith; N L Lehman; R G Moran
Journal:  Cancer Res       Date:  1993-12-01       Impact factor: 12.701

View more
  36 in total

1.  Thieno[2,3-d]pyrimidinedione derivatives as antibacterial agents.

Authors:  Mahender B Dewal; Amit S Wani; Celine Vidaillac; David Oupický; Michael J Rybak; Steven M Firestine
Journal:  Eur J Med Chem       Date:  2012-02-25       Impact factor: 6.514

2.  6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.

Authors:  Lei Wang; Adrianne Wallace; Sudhir Raghavan; Siobhan M Deis; Mike R Wilson; Si Yang; Lisa Polin; Kathryn White; Juiwanna Kushner; Steven Orr; Christina George; Carrie O'Connor; Zhanjun Hou; Shermaine Mitchell-Ryan; Charles E Dann; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2015-08-28       Impact factor: 7.446

3.  Structural determinants of human proton-coupled folate transporter oligomerization: role of GXXXG motifs and identification of oligomeric interfaces at transmembrane domains 3 and 6.

Authors:  Mike R Wilson; Sita Kugel; Jenny Huang; Lucas J Wilson; Patrick A Wloszczynski; Jun Ye; Larry H Matherly; Zhanjun Hou
Journal:  Biochem J       Date:  2015-04-16       Impact factor: 3.857

4.  Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.

Authors:  Manasa Ravindra; Mike R Wilson; Nian Tong; Carrie O'Connor; Mohammad Karim; Lisa Polin; Adrianne Wallace-Povirk; Kathryn White; Juiwanna Kushner; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2018-04-27       Impact factor: 7.446

Review 5.  The Gewald multicomponent reaction.

Authors:  Yijun Huang; Alexander Dömling
Journal:  Mol Divers       Date:  2010-02-27       Impact factor: 2.943

6.  Cellular Pharmacodynamics of a Novel Pyrrolo[3,2-d]pyrimidine Inhibitor Targeting Mitochondrial and Cytosolic One-Carbon Metabolism.

Authors:  Aamod S Dekhne; Changwen Ning; Md Junayed Nayeen; Khushbu Shah; Hasini Kalpage; Josephine Frühauf; Adrianne Wallace-Povirk; Carrie O'Connor; Zhanjun Hou; Seongho Kim; Maik Hüttemann; Aleem Gangjee; Larry H Matherly
Journal:  Mol Pharmacol       Date:  2019-11-09       Impact factor: 4.436

7.  Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter.

Authors:  Christina Cherian; Sita Kugel Desmoulin; Lei Wang; Lisa Polin; Kathryn White; Juiwanna Kushner; Mark Stout; Zhanjun Hou; Aleem Gangjee; Larry H Matherly
Journal:  Cancer Chemother Pharmacol       Date:  2013-02-15       Impact factor: 3.333

8.  Development and validation of chemical features-based proton-coupled folate transporter/activity and reduced folate carrier/activity models (pharmacophores).

Authors:  Khushbu Shah; Sudhir Raghavan; Zhanjun Hou; Larry H Matherly; Aleem Gangjee
Journal:  J Mol Graph Model       Date:  2018-02-20       Impact factor: 2.518

9.  Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.

Authors:  Lei Wang; Christina Cherian; Sita Kugel Desmoulin; Lisa Polin; Yijun Deng; Jianmei Wu; Zhanjun Hou; Kathryn White; Juiwanna Kushner; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

10.  Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.

Authors:  Lalit K Golani; Adrianne Wallace-Povirk; Siobhan M Deis; Jennifer Wong; Jiyuan Ke; Xin Gu; Sudhir Raghavan; Mike R Wilson; Xinxin Li; Lisa Polin; Parker W de Waal; Kathryn White; Juiwanna Kushner; Carrie O'Connor; Zhanjun Hou; H Eric Xu; Karsten Melcher; Charles E Dann; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2016-08-26       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.